Drug Profile
Alzheimer's disease vaccine - Elan
Alternative Names: AIP 001; Amyloid-beta42 vaccine - Elan; AN-1792; AN-1792/QS-21; Aβ42 vaccine; BetablocLatest Information Update: 27 Oct 2009
Price :
$50
*
At a glance
- Originator Elan Pharmaceuticals
- Developer Elan Pharmaceuticals; Wyeth
- Class Vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 26 Jul 2007 Discontinued - Phase-II for Alzheimer's disease in USA (Parenteral)
- 28 Jul 2004 Data presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2004) have been added to the Alzheimer's Disease and Cognition Disorders therapeutic trials section
- 27 Nov 2003 Data presented at the 33rd Annual Meeting of the Society of Neuroscience (AMSN-2003) have been added to the Alzheimer's Disease and Cognition Disorders immunogenicity section